CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <\/p>\n
Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its scientific\/clinical advisory board (SAB). The new members include Kenneth Pienta, M.D.; Jacques Banchereau, Ph.D.; and Karolina Palucka, M.D., Ph.D. These new members join Cues industry-leading SAB, which consists of three experts in immunology, immuno-oncology and protein design. <\/p>\n
We are very pleased with the additional knowledge and expertise that these three leading researchers and clinicians bring to our SAB in the fields of immunology and immuno-oncology, as Cue continues to advance its programs towards the clinic, said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. <\/p>\n
These new scientific\/clinical advisory board members bring invaluable experience that complements our existing members, and we have already begun integrating them into our advisory function, said Steven Almo, Ph.D., Chair of the Department of Biochemistry at Albert Einstein College of Medicine, scientific founder of Cue and Chairman of the Cue Scientific and Clinical Advisory Board. <\/p>\n
Cues scientific and clinical advisory board now contains six leading oncology, immuno-oncology, immunology and protein design experts: <\/p>\n
About Cue Biopharma <\/p>\n
Immune Responses, On Cue. Cue Biopharma(Cue) is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. Cue biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, Cue is led by a strong, experienced management team and scientific\/clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology. <\/p>\n
For more information, visitwww.cuebio.com. <\/p>\n
View source version on businesswire.com: http:\/\/www.businesswire.com\/news\/home\/20170222005333\/en\/<\/a> <\/p>\n <\/p>\n Read the rest here: <\/p>\n Cue Biopharma Strengthens Scientific and Clinical Advisory Board ... - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its scientific\/clinical advisory board (SAB). Continue reading